Arcturus Therapeutics (NASDAQ:ARCT) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report report published on Monday morning,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, November 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Trading Down 5.6 %

Arcturus Therapeutics stock opened at $16.24 on Monday. The firm has a market capitalization of $439.89 million, a P/E ratio of -7.29 and a beta of 2.62. Arcturus Therapeutics has a 1 year low of $14.93 and a 1 year high of $45.00. The business has a 50-day moving average of $18.91 and a 200-day moving average of $22.21.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same period in the previous year, the company earned ($0.61) EPS. Research analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 15.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARCT. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics in the 3rd quarter valued at about $42,000. Quest Partners LLC raised its holdings in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 2,038 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at about $142,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at about $188,000. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.